A Cross-sectional Assessment of Gwalior Residents’ Reports of Adverse Reactions to the COVID-19 Immunization

Rakesh Kumar; Mini Anil; Durlav Singh Parihar; Anshul Garhpale; Sampurna Panda; Babita Panda

doi:10.17485/IJST/v15i44.772

Article

A Cross-sectional Assessment of Gwalior Residents’ Reports of Adverse Reactions to the COVID-19 Immunization

VIEWS 969
PDF 160

Indian Journal of Science and Technology

DOI: 10.17485/IJST/v15i44.772

Year: 2022, Volume: 15, Issue: 44, Pages: 2386-2392

Original Article

A Cross-sectional Assessment of Gwalior Residents’ Reports of Adverse Reactions to the COVID-19 Immunization

Rakesh Kumar¹, Mini Anil¹, Durlav Singh Parihar¹, Anshul Garhpale², Sampurna Panda³, Babita Panda^4*

¹SONS, ITM University, Gwalior, Madhya Pradesh, India
²SOMPS, ITM University, Gwalior, Madhya Pradesh, India
³Research Scholar, Poornima University, Rajasthan, Jaipur, India
⁴KIIT Deemed to be University, Odisha, Bhubaneswar, India

*Corresponding Author
Email: [email protected]

Received Date:07 April 2022, Accepted Date:15 August 2022, Published Date:30 November 2022

This work is licensed under a Creative Commons Attribution 4.0 International License.

Abstract

Objectives: Many people around the world are worried about the safety and adverse effects of the coronavirus SARS CoV2 vaccine. The study’s goal was to document the side effects experienced by Gwalior residents who had received vaccinations. The other objective includes, to evaluate the potential risk factors associated with Covishield and Covaxin vaccination. Methods: Participants who had received one or both doses of any of the provided vaccines were surveyed using a cross-sectional survey (Covaxin, Covishield). The study enrolled 886 people in total. A large majority of those who received the vaccine had never been exposed to SARS CoV2 before (77.2 percent). Covishield (57.6%), followed by Covaxin (42.4%), was the most commonly prescribed medication in the study. Findings: There were several reported side effects following the first dosage of the vaccine, including discomfort at injection site (79.6%), weariness (52.8%), myalgia (36.5%), headache (34.2%), and chills (38.6%). (31.5 percent). Nausea was the most common gastrointestinal adverse effect, with 14.8% of patients reporting it, followed by appetite loss with 8.9% and diarrhea with 8.9%, respectively (5.7 percent). Each of the second doses of immunizations necessitated hospitalization in only one patient. People in Gwalior had higher side effects with the Covishield vaccine than the Covaxin vaccine, according to this research. Novelty: Large sample size and consideration of randomization technique distinguish this work from others. Analysis of Demographic information with GI distress is a newly performed task.

Keywords: Covid19; Vaccine; Side effects; Symptoms; Immunization

References

British Broadcasting Corporation (BBC) News. Covid vaccine: WHO warns of “catastrophic moral failure”. 2021.
Shadmi E, Chen Y, Dourado I, Faran-Perach I, Furler J, Hangoma P, et al. Health equity and COVID-19: global perspectives. International Journal for Equity in Health. 2020;19(104). Available from: https://doi.org/10.1186/s12939-020-01218-z
Khuroo MS, Khuroo MS, Khuroo MS, Sofi AA, Khuroo NS. COVID-19 Vaccines: A Race Against Time in the Middle of Death and Devastation! Journal of Clinical and Experimental Hepatology. 2020;10(6):610–621. Available from: https://doi: 10.1016/j.jceh.2020.06.003
Yoo JH. What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021. Journal of Korean Medical Science. 2021;36(6). Available from: https://doi:10.3346/jkms.2021.36.e54
Jones D, Helmreich S. A history of herd immunity. Lancet. 2020;396(10254):810–811. Available from: https://doi: 10.1016/S0140-6736(20)31924-3
Sprent J, King C. COVID-19 vaccine side effects: The positives about feeling bad. Science Immunology. 2021;6(60). Available from: https://doi:10.1126/sciimmunol.abj9256
Riad A, Pokorná A, Attia S, Klugarová J, Koščík M, Klugar M. Prevalence of COVID-19 Vaccine Side Effects among Healthcare Workers in the Czech Republic. Journal of Clinical Medicine. 2021;10(7):1428. Available from: https://doi.org/10.3390/jcm10071428
Kewei X, Yuanyuan L. A-share Stock Reactions to the Approval of COVID-19 Vaccine Clinical Trial: An Event Study Model of Listed Pharmaceutical Firms’ Returns. 2nd International Conference on Economic Management and Model Engineering (ICEMME). 2020;p. 404–407. Available from: https://doi.org/10.1109/ICEMME51517.2020.00086
Chen L, Wang B, Wang Y, Wang X. Exploratory Data Analysis on the Usage of COVID-19 Vaccine. 6th International Symposium on Computer and Information Processing Technology (ISCIPT). 2021;p. 502–506. Available from: https://doi.org/10.1109/ISCIPT53667.2021.00107
Yang X, Sornlertlamvanich V. Public Perception of COVID-19 Vaccine by Tweet Sentiment Analysis. International Electronics Symposium (IES). 2021;p. 151–155. Available from: https://doi.org/10.1109/IES53407.2021.9594036
Scarabaggio P, Carli R, Cavone G, Epicoco N, Dotoli M. Modeling, Estimation, and Optimal Control of Anti-COVID-19 Multi-dose Vaccine Administration. IEEE 17th International Conference on Automation Science and Engineering (CASE). 2021;p. 990–995. Available from: https://doi.org/10.1109/CASE49439.2021.9551418
Jackson EB, Dreyling R, Pappel I. Challenges and Implications of the WHO’s Digital Cross-Border COVID-19 Vaccine Passport Recognition Pilot. Eighth International Conference on eDemocracy & eGovernment (ICEDEG). 2021;p. 88–94. Available from: https://doi.org/10.1109/ICEDEG52154.2021.9530954
Feng-Cai Z, Yu-Hua L, Xu-Hua G, Li-Hua H, Wen-Juan W, Jing-Xin L, et al. Safety, tolerability, and immunogenicity of a recombinan tadenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. The Lancet. 2020;395(10240):1845–1854. Available from: https://doi.org/10.1016/S0140-6736(20)31208-3
Zhai P, Ding Y, Wu X, Long J, Zhong Y, Li Y. The epidemiology, diagnosis and treatment of COVID-19. International Journal of Antimicrobial Agents. 2020;55(5):105955. Available from: https://doi.org/10.1016/j.ijantimicag.2020.105955
Yoshimoto FK. The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or n-COV19), the Cause of COVID-19. The Protein Journal. 2020;39(3):198–216. Available from: https://doi.org/10.1007/s10930-020-09901-4
Figueroa‐hurtado E, Ortíz‐farias DL, Sada‐ovalle I, Maldonado‐ortíz SY, Valdivieso‐jiménez JA, Cortes‐telles A. Humoral immune response in healthcare workers after two doses of a <scp>BNT162b2 mRNA</scp> vaccine in Yucatan, Mexico. Respirology Case Reports. 2022;10. Available from: https://doi.org/10.1002/rcr2.920
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422. Available from: https://doi.org/10.1016/S2213-2600(20)30076-X
Daniel W, Nianshuang W, Kizzmekia C, Goldsmith S, JA, Ching-Lin H, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–1263. Available from: https://doi: 10.1126/science.abb2507

Copyright

© 2022 Kumar et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Published By Indian Society for Education and Environment (iSee)